Parameter | Full Dose Group (N = 233) | Reduced Dose Group (N = 205) | P value |
---|---|---|---|
Age at transplantation (years) (mean ± SD, range) | 52.5 ± 13 (19–81) | 54.1 ± 12 (24–76) | 0.22 |
Sex (N, %) | 0.42 | ||
Male | 144 (62) | 119 (58) | |
Female | 89 (38) | 86 (42) | |
Donor Source (N, %) | 0.002 | ||
Deceased | 142 (61) | 154 (75) | |
Live | 91 (39) | 51 (25) | |
Number of transplants | 0.4 | ||
One | 224 (97) | 194 (96) | |
Two | 7 (3) | 9 (4) | |
Cause of end-stage kidney disease (N, %) | |||
Diabetes | 41 (18) | 44 (22) | 0.30 |
Hypertension | 25 (11) | 19 (9) | 0.61 |
Glomerulonephritis | 94 (40) | 78 (38) | 0.62 |
Polycystic kidney disease | 23 (10) | 28 (14) | 0.21 |
Congenital kidney disease | 10 (4) | 7 (3) | 0.63 |
Others | 40 (17) | 29 (14) | 0.28 |
Ethnicity | |||
Caucasian | 94 (40) | 70 (34) | 0.13 |
Black | 16 (7) | 21 (10) | 0.20 |
East Asian | 32 (14) | 20 (10) | 0.19 |
South Asian | 47 (20) | 53 (26) | 0.15 |
Other | 43 (19) | 41 (20) | 0.71 |
Pre-transplant dialysis modality (N, %) | 0.015 | ||
Hemodialysis | 122 (53) | 131 (64) | |
Peritoneal dialysis | 69 (30) | 54 (27) | |
Preemptive | 36 (17) | 18 (9) | |
Dialysis duration (days) (mean ± SD) | 1790 ± 1315 | 2052 ± 1427 | 0.06 |
Cytomegalovirus IgG antibody N (%) | 174 (75) | 167 (81) | 0.18 |
Epstein Barr virus IgG antibody N (%) | 211 (91) | 189 (93) | 0.70 |
Hepatitis B surface antigen N (%) | 4 (2) | 3 (1) | 0.29 |
Hepatitis C antibody N (%) | 4 (2) | 2 (1) | 0.41 |
HIV antibody N (%) | 2 (1) | 4 (2) | 0.29 |
Tuberculin skin test positive N (%) | 31 (13) | 11 (5) | 0.33 |
Cumulative Panel Reactive Antibody (%)(mean ± SD, range) | 7.5 ± 20 (0–99) | 13.5 ± 28 (0–100) | 0.02 |
History of smoking (N, %) | 94 (42) | 56 (28) | 0.003 |
Delayed graft function N (%) | 38 (16) | 41 (20) | 0.31 |
Acute rejection N (%) | 7 (3) | 18 (9) | 0.009 |
Post-transplant diabetes (N, %) | 19 (8) | 16 (8) | 0.81 |
Graft loss N (%) | 2 (1) | 0 (0) | 0.28 |
Immunosuppressive medication at discharge (N, %) | |||
Tacrolimus | 215 (93) | 189 (93) | 0.99 |
Cyclosporine | 11 (5) | 14 (7) | 0.34 |
Mycophenolate mofetil | 104 (45) | 80 (39) | 0.23 |
or mycophenolic acid | 103 (45) | 95 (44) | 0.64 |
Azathioprine | 11 (5) | 4 (2) | 0.09 |
Prednisone | 219 (95) | 196 (97) | 0.37 |
Other medication (N, %) | |||
Angiotensin-converting enzyme inhibitor | 12 (5) | 9 (4) | 0.71 |
Angiotensin II receptor blocker | 19 (8) | 24 (12) | 0.21 |
Non-dihydropyridine calcium channel blocker | 21 (9) | 13 (6) | 0.28 |
Dihydropyridine calcium channel blocker | 100 (43) | 100 (49) | 0.21 |
Beta blocker | 87 (37) | 90 (44) | 0.15 |
Alpha blocker | 23 (10) | 19 (9) | 0.83 |
Loop diuretic | 10 (4) | 12 (6) | 0.29 |
Thiazide diuretic | 4 (2) | 4 (2) | 0.56 |